In breast cancer, ANRIL was found to be predominantly located in the nucleus, and nuclear ANRIL positively correlated with periostin expression, suggesting that the subcellular localization of ANRIL impacts cancer progression (89). Here, CDKN2B-AS1 is linked to breast cancer.